Ideaya Biosciences, Genentech launch Phase 1 combo trial in KRAS G12D PDAC
Ideaya Biosciences (IDYA) announces a clinical collaboration with Genentech to sponsor a jointly governed trial and plan a Phase 1 combination cohort with Roche’s rg6505 in mtap-deleted, KRAS G12D mutant pancreatic cancer in 2H 2026.